Vaxart reports Q2 2026 net loss $13.5M; Phase 2b sentinel safety data positive

Vaxart, Inc.

Net loss $13.5M ($0.06 per share) vs $15.0M loss in Q2 2025; revenue $27.2M (down from $39.7M).
Cash $64.0M; runway into Q2 2027; BARDA contract total authorized funding $344.8M.
Phase 2b sentinel cohort (400 participants) showed no vaccine-related SAEs; most common AEs: fatigue, headache.
Topline efficacy data from full ~5,000-participant study expected H1 2027.
R&D expenses $33.7M (down 32% YoY); G&A $6.6M (up 43% YoY).

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.